Imaging with radiolabelled bisphosphonates.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32353566.
- Also identified by DOI 10.1016/j.bone.2020.115372 and PMC identifier 7616182.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Radiolabeled bisphosphonates were developed in the 1970s for scintigraphic functional imaging of the skeleton in benign and malignant disease. Tracers such as <sup>99m</sup>Tc-methylene diphosphonate, that map focal or global changes in mineralization in the skeleton qualitatively and quantitatively, have been the backbone of nuclear medicine imaging for decades. While competing technologies are evolving, new indications and improvements in scanner hardware, in particular hybrid imaging (e.g. single photon emission computed tomography combined with computed tomography), have allowed improved diagnostic accuracy and a continued role for radiolabeled bisphosphonate imaging in current practice.
Medical subject headings
- Diphosphonates
- Tomography, Emission-Computed, Single-Photon